NKGen Biotech's Alzheimer's Breakthrough: Why This Stock Could Be a Winner in the Growing Neurology Market

Investors seeking exposure to the exploding Alzheimer's therapeutics market should take note: NKGen Biotech is primed to deliver a game-changing therapy through its Phase 1/2a trial expansion for troculeucel, an autologous natural killer (NK) cell therapy targeting neuroinflammation and protein aggregates linked to Alzheimer's disease (AD). With strategic geographic expansions, clinical validation milestones, and a $15 billion market on the horizon, this is a stock to watch closely.

### The Strategic Play: Expanding Trials to Accelerate Recruitment
NKGen's trial expansion adds two critical sites: Canada's Ottawa Memory Clinic, led by Dr. Richard Bergeron—a neuroscientist with over 60 years of experience—and AdventHealth Orlando in Florida. These locations are no accident. The Canadian site secures Health Canada approval, broadening patient diversity and tapping into a region with high AD prevalence. The U.S. site, managed by Dr. Anita Fletcher, strengthens East Coast recruitment, accelerating enrollment toward the trial's 80-patient target.

This geographic push isn't just about numbers—it's about credibility. Dr. Bergeron, CEO of both Ottawa and Montreal Memory Clinics, brings unmatched expertise in managing multinational trials. His leadership signals to investors that NKGen is serious about scaling globally, a critical step for a therapy aiming to address AD's rising global burden.



### Clinical Validation: Safety, Biomarkers, and a Path to Efficacy
The Phase 1 data is a big win for NKGen. Troculeucel demonstrated no drug-related adverse events in 100% of participants, establishing a strong safety profile. Even more promising: 90% of patients showed stable or improved cognitive function. Biomarker data is equally compelling. In cerebrospinal fluid (CSF), troculeucel reduced neuroinflammatory markers like pTau181 and GFAP, suggesting it could slow AD's progression.

This isn't incremental progress. Current AD drugs, like cholinesterase inhibitors, only manage symptoms—they don't address underlying pathology. Troculeucel's focus on neuroinflammation and protein aggregates represents a novel mechanism of action, a critical differentiator in a crowded field dominated by amyloid-targeting therapies (e.g., Biogen's Aduhelm).

### The Alzheimer's Market: A $15 Billion Opportunity by 2030
The Alzheimer's therapeutics market is on fire. Projections estimate it will grow from $4.8 billion in 2023 to over $15 billion by 2030, fueled by an aging population and rising awareness of early-onset cases. North America leads the market today, but Asia-Pacific's growth is explosive—China and India alone account for 20% of global AD patients.

Here's the kicker: Current treatments are a stopgap. Cholinesterase inhibitors (e.g., donepezil) dominate sales but only mask symptoms. Pipeline drugs like lecanemab (Eisai/Biogen) and aducanumab (Biogen) target amyloid plaques but have mixed clinical results and steep price tags. Troculeucel's ability to address inflammation—a key driver of AD progression—positions it as a complementary or superior therapy.



### Upcoming Catalysts: Data Milestones and Strategic Partnerships
Investors should mark their calendars for Q3 2025, when NKGen will report initial biomarker data from the Phase 1/2a trial. Positive results here could trigger a stock surge, especially if reductions in pTau181 or GFAP align with Phase 1 trends.

Longer term, the trial's dose-escalation design aims to identify the optimal dose (RP2D) by early 2026. A successful RP2D could lead to Phase 3 planning, a key step toward regulatory submissions. Additionally, NKGen's partnership opportunities are vast. Collaborations with diagnostics firms (e.g., Roche's CSF tests) or big pharma (looking to diversify beyond amyloid) could unlock value.

### Risks? Yes—but the Upside Outweighs Them
Risks include competition from amyloid-targeted drugs, potential delays in recruitment, and the need for funding. However, NKGen's robust Phase 1 data, strategic site expansions, and the lack of effective alternatives make these manageable.

### Buy, Hold, or Sell?
This is a buy for growth investors with a 12–18 month horizon. Key catalysts—Q3 biomarker data, Phase 3 path clarity—could double the stock if met. Longer term, a successful therapy in a $15 billion market could make NKGen a takeover target or a leader in neurodegenerative therapies.

Act now: Alzheimer's is a ticking time bomb. NKGen's science and execution put it at the vanguard of a $15 billion opportunity. Don't miss the boat.

---
Investment advice disclaimer: Past performance is not indicative of future results. Always conduct your own research or consult a financial advisor before making investment decisions.